CTI BioPharma Corp.

CTI BioPharma Corp.

CTI BioPharma Corp.

Overview
Date Founded

2017

Headquarters

3101 Western Avenue,Suite 600,Seattle, WA 98121

Type of Company

Public

Employees (Worldwide)

25

Industries

Pharmaceuticals
Hospitals & Patient Services
Biotechnology

Company Description

CTI BioPharma Corp. is a biopharmaceutical company, which focuses on the development, acquisition and commercialization of novel targeted therapies for blood-related cancers. It focuses on evaluating pacritinib, its sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA.

Contact Data
Trying to get in touch with decision makers at CTI BioPharma Corp.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

President & Chief Executive Officer

Executive Vice President & Chief Financial Officer

Executive Vice President & Chief Operating Officer

Senior Vice President, Corporate Communications & Investor Relations

Senior Vice President, Global Operations

Senior Vice President, Strategic Operations

Senior Vice President, Biometrics

Vice President, Clinical Operations, PV & Quality

Head-Investor Relations

Head of Legal Affairs

Board of Directors

Chief Executive Officer at Adverum Biotechnologies, Inc.

President at American Telemedicine Association

President & Portfolio Manager at BVF Partners LP

Director, President & Chief Operating Officer at Syndax Pharmaceuticals, Inc.

Co-Founder, Director at Refuge Biotechnologies, Inc.

President & Chief Executive Officer at CTI BioPharma Corp.

Executive Vice President & Chief Financial Officer at CTI BioPharma Corp.

Paths to CTI BioPharma Corp.
Potential Connections via
Relationship Science
You
CTI BioPharma Corp.
Owners & Shareholders
Details Hidden

New Enterprise Associates seeks invests in companies located across the globe. The firm targets companies operating in the fields of technology (software & services, systems, consumer & internet, energy), healthcare (biopharms, devices, services). The firm provides financing for seed, early and growth stage capital requirements.

Details Hidden

BVF Partners pursues value-oriented investment strategies, investing primarily in the marketable securities issued by biotechnology companies. The firm's investments within the biotechnology sector focus primarily on the securities of companies with market capitalizations of less than $1 billion. BVF may also invest in unregistered securities of public and closely-held private biotechnology companies by directly purchasing from issuers or other shareholders, in privately negotiated transactions, common stock, convertible preferred stock and/or debt instruments with warrants, options and/or similar rights to acquire an equity interest. The firm also pursues a second investment strategy on that invests in equity or equity-linked securities of companies involved in the biotechnology industry and related fields that, as of the time of the acquisition of such securities, have a market capitalization of $350 million to $3 billion.

Details Hidden

Founded in 1983, Caxton Corp. is an investment advisor located in Princeton, New Jersey.

Recent Transactions
Details Hidden

Les Laboratoires Servier SAS, Servier Laboratories Ltd. purchase Cti Biopharma Corp. /Pixuvri from CTI BioPharma Corp.

Details Hidden

CTI BioPharma Corp. issued USD Common Stock

Details Hidden

CTI BioPharma Corp. raised money in a private placement transaction

Insider Transactions
Details Hidden
Transaction Advisors
Accountant

Advised onCTI BioPharma Corp. purchases Novuspharma SpA

Underwriter

Advised onCTI BioPharma Corp. issued USD Common Stock

Underwriter

Advised onCTI BioPharma Corp. issued USD Common Stock

Legal Advisor

Advised onCephalon, Inc. purchases Cell Therapeutics, Inc. /TRISENOX Operation from CTI BioPharma Corp.

Senior Managing Director

Advised onCTI BioPharma Corp. issued USD Common Stock

Legal Advisor

Advised onCTI BioPharma Corp. issued USD Common Stock

Advisors & Consultants
Legal Advisor

Partner at Wilson Sonsini Goodrich & Rosati PC

Legal Advisor

Partner at Wilson Sonsini Goodrich & Rosati PC

Legal Advisor

Partner at Orrick, Herrington & Sutcliffe LLP

Clients

Les Laboratoires Servier SAS manufactures medicines for the treatment of diabetes, venous disease, and cancer. It also offers pharmaceutical products for cardiovascular illnesses such as hypertension, heart failure, and stroke. The company was founded by Jacques Servier in 1954 and is headquartered in Suresnes, France.

Baxalta, Inc. engages in the research, development, and manufacture of biopharmaceutical products. Its portfolio includes treatments for hemophilia, bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns, and shock. The company was founded on March 13, 2015 and is headquartered in Chicago, IL.

Key Stats and Financials As of 2019
Market Capitalization
$245M
Total Enterprise Value
$66.4M
Earnings Per Share
$-0.69
Three Year Compounded Annual Growth Rate Of Revenue
-61.23%
Debt TEV
0.21x
TEVNet Income
-1.66x
Enterprise Value / Sales
19.85x
Total Equity
$17.9M
Total Debt
$14.2M
EBITDAMargin
-1,177.01%
EBITDA
$-39.4M
Net Profit
$-40M
Revenue
$3.34M
Non-Profit Donations & Grants
$10K - $50K
2014
Suppliers
Vernalis Ltd. Wholesale: Consumer Non-Durables/Sundries | Great Abington, United Kingdom

Vernalis Ltd. is a commercial stage pharmaceutical company. Its products include Tuzistra XR, targeting the U.S. prescription cough-cold market; Moxatag, a once-a-day formulation of the antibiotic and amoxicillin; and frovatriptan, used for the acute treatment of migraine. Vernalis also develops and commercializes multiple novel products focused on the U.S. prescription cough-cold market. The company was founded by Keith G. McCullagh and Andre L. Lamotte in 1986 and is headquartered in Winnersh, the United Kingdom.

Innophos Holdings, Inc. Holding Companies | Cranbury, NJ

Innophos is a leading producer of specialty grade phosphate products for the Food, Pharmaceutical and Industrial market segments. Within these segments our products cover a broad range of applications including water, paper and metal treatment, agriculture, electronics, textiles, tablets, meat preservation and detergents. For example, specialty phosphates act as flavor enhancers in beverages, leavening agents in baked goods and cleaning agents in toothpaste. With over a century of experience, Innophos and its predecessor companies have pioneered the processes whereby complex phosphates are derived from organic phosphate rock. Our products are produced to the highest standards of quality and consistency with most of our global production facilities operating to ISO 9002 and GMP accreditation. We also hold a number of key patents governing the manufacture and use of phosphates and continue to develop new and innovative phosphate based products to address specific customer applications.

Ligand Pharmaceuticals, Inc. Medical Support Services | La Jolla, CA

Ligand Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and acquisition of technologies that help pharmaceutical companies to discover and develop medicines. Its products include evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was founded by Ronald M. Evans in 1987 and is headquartered in San Diego, CA.

Competitors
Novartis AG Pharmaceuticals - Basel, Switzerland

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Bristol-Myers Squibb Company Pharmaceuticals - New York, New York

Bristol-Myers Squibb Company Our company has a strong legacy of innovation that began in New York in 1858 when Edward R. Squibb, M.D., founded a pharmaceutical company in Brooklyn, and in 1887 when two friends, William McLaren Bristol and John Ripley Myers purchased a struggling drug manufacturing firm in Clinton. Together, they laid the foundation for our company today — a global BioPharma leader that continues this legacy of innovation.

Incyte Corp. Pharmaceuticals - Wilmington, DE

Incyte's vision is to become a leading drug discovery, development and commercial company by building a proprietary product pipeline of novel small molecule drugs for serious unmet medical needs. We have experienced management, discovery, clinical development and commercial teams. Our assets, experience and prior success in bringing important new drugs to market put us in a strong position to make a difference in health care, improve the lives of patients and build sustainable value for our shareholders. Our pipeline is focused on oncology and inflammation and includes compounds in various stages of development. Our lead product, Jakafi® (ruxolitinib), a JAK1 and JAK2 inhibitor, is currently approved in the United States for the treatment of intermediate or high-risk myelofibrosis (please see Full Prescribing Information and Important Safety Information for Jakafi) and is in development as a potential treatment for other cancers. We have established multiple collaborations with major pharmaceutical companies to support the clinical development and global commercialization of several of our compounds. Through strategic collaborations with Novartis and Eli Lilly, we are advancing the global development of two of our JAK1 and JAK2 inhibitor programs. Incyte's corporate headquarters is located in Wilmington, Delaware

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by CTI BioPharma Corp.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of CTI BioPharma Corp.'s profile does not indicate a business or promotional relationship of any kind between RelSci and CTI BioPharma Corp..